Journal of the National Comprehensive Cancer Network : JNCCN This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical Risks for Chronic Lymphocytic Leukemia
J Natl Compr Canc Netw. 2024 Apr;22(3):e247020. doi: 10.6004/jnccn.2024.7020.ABSTRACTOur understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation. Environmental factors have also been challenging to identify given the limited understanding of the...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: Jennifer R Brown Source Type: research

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.ABSTRACTChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: William G Wierda Jennifer Brown Jeremy S Abramson Farrukh Awan Syed F Bilgrami Greg Bociek Danielle Brander Matthew Cortese Larry Cripe Randall S Davis Herbert Eradat Bita Fakhri Christopher D Fletcher Sameh Gaballa Muhammad Saad Hamid Brian Hill Paul Kae Source Type: research

Prostate Cancer, Version 3.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019.ABSTRACTThe NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.PMID:38626801 | DOI:10.6004/jnccn.2024.0019 (Source: Journal of the National Comprehens...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: Edward M Schaeffer Sandy Srinivas Nabil Adra Yi An Rhonda Bitting Brian Chapin Heather H Cheng Anthony Victor D'Amico Neil Desai Tanya Dorff James A Eastham Thomas A Farrington Xin Gao Shilpa Gupta Thomas Guzzo Joseph E Ippolito R Jeffrey Karnes Michael R Source Type: research

Aligning With the National Cancer Plan
J Natl Compr Canc Netw. 2024 Apr;22(3):139. doi: 10.6004/jnccn.2024.0020.NO ABSTRACTPMID:38626805 | DOI:10.6004/jnccn.2024.0020 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: Erin Frantz Rachel Darwin Kimberly Callan Wui-Jin Koh Source Type: research

The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals
CONCLUSIONS: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV+/FPC+, and PGV+/FPC- risk groups by surveillance protocols.PMID:38626807 | DOI:10.6004/jnccn.2023.7097 (Source: Journa...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: George Zogopoulos Ido Haimi Shenin A Sanoba Jessica N Everett Yifan Wang Bryson W Katona James J Farrell Aaron J Grossberg Salvatore Paiella Kelsey A Klute Yan Bi Michael B Wallace Richard S Kwon Elena M Stoffel Raymond C Wadlow Daniel A Sussman Nipun B M Source Type: research

CRE24-048: Unmasking the Unpredictable: Spontaneous Tumor Lysis Syndrome in Metastatic Breast Cancer-A Case Beyond Expectations
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CRE24-048. doi: 10.6004/jnccn.2023.7314.NO ABSTRACTPMID:38580247 | DOI:10.6004/jnccn.2023.7314 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Paridhi Ghai Amy Gates Source Type: research

EPR24-103: Casting Light on Metastatic Kidney Cancer Survival: A Gender-Based Examination
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):EPR24-103. doi: 10.6004/jnccn.2023.7214.NO ABSTRACTPMID:38580248 | DOI:10.6004/jnccn.2023.7214 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Jerry Kenmoe Calvin Ghimire Alexander Rabadi Anjela Shrestha Arvind Kunadi Source Type: research

CRE24-053: Brown Fat Adipose Tissue (BAT) Activation Mimicking Lymphoma-Associated Lymphadenopathy
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CRE24-053. doi: 10.6004/jnccn.2023.7327.NO ABSTRACTPMID:38580249 | DOI:10.6004/jnccn.2023.7327 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Mrunal Patel Fehmida Laxmidhar Khushboo Lakhatariya Rushin Patel Source Type: research

HSR24-128: Real-World Treatment Patterns and Effectiveness of Selpercatinib in Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer in the US
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):HSR24-128. doi: 10.6004/jnccn.2023.7200.NO ABSTRACTPMID:38580250 | DOI:10.6004/jnccn.2023.7200 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Chi-Yin Liao Carmen Gonzalez-Ferrer Samuel Whipple Naleen Raj Bhandari Patrick M Peterson Scott S Barker Feng Wang Source Type: research

CRE24-052: Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CRE24-052. doi: 10.6004/jnccn.2023.7326.NO ABSTRACTPMID:38580251 | DOI:10.6004/jnccn.2023.7326 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Aaron Charles Lobo Zeynep Busra Zengin Charles Kenworthy Anish Sharda Source Type: research

QIM24-179: Instituting Quality Improvement Processes With Periprocedural Heparin Infusions at a Major Cancer Center Utilizing a Failure Mode and Effects Analysis
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):QIM24-179. doi: 10.6004/jnccn.2023.7154.NO ABSTRACTPMID:38580252 | DOI:10.6004/jnccn.2023.7154 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Christy Thai James Lochner Katherine Helsel Misbahuddin Syed Source Type: research

QIM24-178: Managing Pharmaceutical Costs in the Oncology Care Model
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):QIM24-178. doi: 10.6004/jnccn.2023.7175.NO ABSTRACTPMID:38580253 | DOI:10.6004/jnccn.2023.7175 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Grant Andres Christine Bates Cyndie Harrelson Kate Wallace Ann Sweeney Meredith Jones Karen Miller Marti Larriva Susan Meyer Tiffany Mitchem Jody Agena Puneeth Indurlal Source Type: research

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CLO24-079. doi: 10.6004/jnccn.2023.7228.NO ABSTRACTPMID:38580254 | DOI:10.6004/jnccn.2023.7228 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Yazan Madanat Michael R Savona Mikkael A Sekeres Uwe Platzbecker Valeria Santini Pierre Fenaux Maria Diez-Campelo David Valc árcel Tymara Berry Souria Dougherty Sheetal Shah Libo Sun Ying Wan Fei Huang Shyamala Navada Rami S Komrokji Amer M Zeidan Source Type: research

BPI24-012: Comparing Cancer Risk Management Between Females With Truncating CHEK2 1100delC Versus Missense CHEK2 I157T Variants
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):BPI24-012. doi: 10.6004/jnccn.2023.7304.NO ABSTRACTPMID:38580255 | DOI:10.6004/jnccn.2023.7304 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Diego Garmendia Anne Weidner Lindsay Venton Tuya Pal Source Type: research

CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CLO24-060. doi: 10.6004/jnccn.2023.7199.NO ABSTRACTPMID:38580256 | DOI:10.6004/jnccn.2023.7199 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Chalothorn Wannaphut Chanakarn Kanitthamniyom Penvadee Pattanaprichakul Smith Kungwankiatichai Weerapat Owattanapanich Source Type: research